Amarantus Bioscience Holdings Inc (AMBS)

[Calm68]

AMBS has multiple pathways in both diagnostics and in therapeutics. They have well articulated the plan on Lympro, 2 orphan indication pathways with MANF, a highly competent team surrounding the entire project, have made tremendous progress in the last 10 months. To me at .042 this is a screaming buy. If this drops to the low .03's I would be tempted to sell all my other holdings to go all in here.